PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA
Abstract
Authors
V. Omelyanovskiy M. Avxentyeva M. Sura A.G. Savilova G.R. Khachatryan